Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development

Journal of Pathology

Volumn 236, Issue 3, 2015, Pages 278-289

  Wang, Qian ^a,b   Hardie, Rae Anne ^a,b   Hoy, Andrew J ^c   Van Geldermalsen, Michelle ^a,b   Gao, Dadi ^a,b   Fazli, Ladan ^d   Sadowski, Martin C ^e   Balaban, Seher ^c   Schreuder, Mark ^c   Nagarajah, Rajini ^a,b   Wong, Justin J L ^a,b   Metierre, Cynthia ^a,b   Pinello, Natalia ^a,b   Otte, Nicholas J ^a,b   Lehman, Melanie L ^e   Gleave, Martin ^d   Nelson, Colleen C ^e   Bailey, Charles G ^a,b   Ritchie, William ^a,b   Rasko, John Ej ^a,b,f   Holst, Jeff ^a,b   more..

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

ASCT2; cell cycle; glutamine; metabolism; prostate cancer; SLC1A5

Indexed keywords

AMINO ACID TRANSPORTER; ASCT2 PROTEIN; GLUTAMINE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; FATTY ACID; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; OXYGEN; SLC1A5 PROTEIN, HUMAN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL METABOLIC RATE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; XENOGRAFT;

AMINO ACID TRANSPORT SYSTEM ASC; ANIMALS; BIOLOGICAL TRANSPORT; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FATTY ACIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLUTAMINE; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, NUDE; MULTIPROTEIN COMPLEXES; NEOPLASM METASTASIS; OXYGEN; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TOR SERINE-THREONINE KINASES;

EID: 84930482603     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4518     Document Type: Article

References (40)

1. Mullen AR, Wheaton WW, Jin ES, et al., Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012; 481: 385-388.
2. Fendt SM, Bell EL, Keibler MA, et al., Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res 2013; 73: 4429-4438.
3. Csibi A, Fendt SM, Li C, et al., The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013; 153: 840-854.
4. Dang CV,. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010; 70: 859-862.
5. Gao P, Tchernyshyov I, Chang TC, et al., c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458: 762-765.
6. Wise DR, DeBerardinis RJ, Mancuso A, et al., Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 2008; 105: 18782-18787.
7. Gurel B, Iwata T, Koh CM, et al., Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008; 21: 1156-1167.
8. Blando J, Portis M, Benavides F, et al., PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol 2009; 174: 1869-1879.
9. Demetriades C, Doumpas N, Teleman AA,. Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2. Cell 2014; 156: 786-799.
10. Menon S, Dibble CC, Talbott G, et al., Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 2014; 156: 771-85.
11. Sancak Y, Bar-Peled L, Zoncu R, et al., Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010; 141: 290-303.
12. Sancak Y, Peterson TR, Shaul YD, et al., The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008; 320: 1496-1501.
13. +-ATPase. Science 2011; 334: 678-683.
14. Duran RV, Oppliger W, Robitaille AM, et al., Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 2012; 47: 349-358.
15. Nicklin P, Bergman P, Zhang B, et al., Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521-534.
16. Kekuda R, Prasad PD, Fei YJ, et al., Cloning of the sodium-dependent, broad-scope, neutral amino acid transporter Bo from a human placental choriocarcinoma cell line. J Biol Chem 1996; 271: 18657-18661.
17. Li R, Younes M, Frolov A, et al., Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res 2003; 23: 3413-3418.
18. Wang Q, Beaumont KA, Otte NJ, et al., Targeting glutamine transport to suppress melanoma cell growth. Int J Cancer 2014; 135: 1060-1071.
19. Willems L, Jacque N, Jacquel A, et al., Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 2013; 122: 3521-3532.
20. Hassanein M, Hoeksema MD, Shiota M, et al., SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res 2013; 19: 560-570.
21. Ren P, Yue M, Xiao D, et al., ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. J Pathol 2015; 235: 90-100.
22. Kaira K, Sunose Y, Arakawa K, et al., Clinicopathological significance of ASC-amino acid transporter 2 (ASCT2) expression in pancreatic ductal carcinoma. Histopathology 2015; 66: 234-243.
23. Wang Q, Tiffen J, Bailey CG, et al., Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. J Natl Cancer Inst 2013; 105: 1463-1473.
24. Qi J, Tripathi M, Mishra R, et al., The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell 2013; 23: 332-346.
25. +-dependent anion leak. J Physiol 2004; 557: 747-759.
26. Hara K, Yonezawa K, Weng QP, et al., Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998; 273: 14484-14494.
27. Kimball SR, Shantz LM, Horetsky RL, et al., Leucine regulates translation of specific mRNAs in L6 myoblasts through mTOR-mediated changes in availability of eIF4E and phosphorylation of ribosomal protein S6. J Biol Chem 1999; 274: 11647-11652.
28. Esslinger CS, Kimberly AC, Joseph FR,. Nγ-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Bioorg Med Chem 2005; 13: 1111-1118.
29. Dixon SJ, Patel DN, Welsch M, et al., Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 2014; 3: e02523.
30. Tiffen JC, Bailey CG, Ng C, et al., Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol Cancer 2010; 9: 299.
31. Reynolds MR, Lane AN, Robertson B, et al., Control of glutamine metabolism by the tumor suppressor Rb. Oncogene 2014; 33: 556-566.
32. Wang Q, Bailey CG, Ng C, et al., Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res 2011; 71: 7525-7536.
33. Fuchs BC, Bode BP,. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 2005; 15: 254-266.
34. Morita M, Gravel SP, Chenard V, et al., mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab 2013; 18: 698-711.
35. Cunningham JT, Rodgers JT, Arlow DH, et al., mTOR controls mitochondrial oxidative function through a YY1-PGC-1α transcriptional complex. Nature 2007; 450: 736-740.
36. Singleton DC, Harris AL,. Targeting the ATF4 pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 1189-1202.
37. Qing G, Li B, Vu A, et al., ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 2012; 22: 631-644.
38. +-dependent anion leak. J Physiol 2004; 557: 747-759.
39. Oppedisano F, Catto M, Koutentis P, et al., Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity. Toxicol Appl Pharmacol 2012; 265: 93-102.
40. Nakaya M, Xiao Y, Zhou X, et al., Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity 2014; 40: 692-705.